drugset / Trial / NCT05674253

Combined Use of Dexmedetomidine and Hydrocortisone to Prevent New Onset AF After CABG Surgery

NCT05674253

Phase 0 Unknown 248 enrolled Ain Shams University
RandomizedParallel-groupSingle-blindPrevention

Summary

Atrial fibrillation (AF) occurs in 20% to 40% of patients after Coronary artery bypass grafting (CABG) and is associated with numerous detrimental sequelae. In postoperative period, the patient may be exposed to several proarrhythmogenic factors as increased endogenous catecholamines, inflammatory and oxidative mediators secondary to surgical stress and the systemic response to cardiopulmonary bypass, use of inotropic support. Steroids suppress the release of the above-mentioned inflammatory mediators. Dexmedetomidine is sympatholytic, along with anti-inflammatory properties. so combined use of both drugs may have synergistic effect to prevent post operative AF (POAF)

Timeline

Start
2022-12-25
Primary completion
2023-06-25
Completion
2023-07-25

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 0.7 ug/kg Intravenous
Comparator Hydrocortisone Other / unclassified 100 mg Intravenous

Indications